DUBLIN – Sofinnova Partners has raised €275 million (US$339 million) for a new health care crossover fund, Sofinnova Crossover I, which will fund late-stage biotechnology and medical device firms that have proof-of-concept data in hand and have an eye on a Nasdaq listing within 12 to 18 months.